Australia's biotech sector has no shortage of good ideas with a total of 30 new companies listing on ASX over the past 20 months. But with too many immature companies, and not enough sophisticated investors, the sector is struggling to achieve stability and growth.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Australia considers revised scheme for young researchers
Related external links
Rights and permissions
About this article
Cite this article
O'Neill, G. Australian biotech suffers growing pains. Nat Biotechnol 23, 401–402 (2005). https://doi.org/10.1038/nbt0405-401
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0405-401